Researcher
Gregor Verhoef
- Disciplines:Laboratory medicine, Palliative care and end-of-life care, Regenerative medicine, Other basic sciences, Other health sciences, Nursing, Other paramedical sciences, Other translational sciences, Other medical and health sciences
Affiliations
- Laboratory of Experimental Hematology (Division)
Member
From1 Oct 2013 → Today
Projects
1 - 5 of 5
- Genetic drivers of peripheral T-cell lymphomagenesisFrom1 Sep 2017 → 23 Nov 2022Funding: Foundations, funds and other with scientific goal
- The molecular landscape of rare aggressive lymphomasFrom1 Aug 2017 → 1 Dec 2019Funding: Own budget, for example: patrimony, inscription fees, gifts
- Post-transplant lymphoproliferative disorders: a single center experience over 20 years.From1 Jan 2011 → 31 Dec 2016Funding: FWO research project (including WEAVE projects)
- Physical activity and physical fitness in lymphoma patients before, during and after treatment - a prospective observational study.From1 Oct 2010 → 1 Jun 2013Funding: FWO fellowships
- Whole-body diffusion-weighted MRI in malignant lymphoma: staging and early treatment response assessmentFrom1 Oct 2010 → 8 Jan 2018Funding: Own budget, for example: patrimony, inscription fees, gifts
Publications
1 - 10 of 170
- The iR2 regimen (ibrutinib plus lenalidomide and rituximab) for relapsed/refractory DLBCL: a multicentre, non-randomised, open-label phase 2 study(2023)
Authors: Gregor Verhoef
- [18F]FDG-PET/CT volumetric parameters can predict outcome in untreated mantle cell lymphoma(2023)
Authors: Vibeke Vergote, Gregor Verhoef, Ann Janssens, Annouschka Laenen, Thomas Tousseyn, Daan Dierickx, Christophe Deroose
Pages: 161 - 170 - Characteristics and Outcome of Post-Transplant Lymphoproliferative Disorders After Solid Organ Transplantation: A Single Center Experience of 196 Patients Over 30 Years(2022)
Authors: Vibeke Vergote, Christophe Deroose, Steffen Fieuws, Wim Laleman, Anne Uyttebroeck, Gregor Verhoef, Robin Vos, Thomas Tousseyn, Daan Dierickx
- Genetic drivers of peripheral T-cell lymphomagenesis(2022)
Authors: Koen Debackere, Daan Dierickx, Gregor Verhoef, Jan Cools
- Avelumab in Combination Regimens for Relapsed/Refractory DLBCL: Results from the Phase Ib JAVELIN DLBCL Study(2021)
Authors: Gregor Verhoef
Pages: 761 - 771 - Fusion transcripts FYN-TRAF3IP2 and KHDRBS1-LCK hijack T cell receptor signaling in peripheral T-cell lymphoma, not otherwise specified(2021)
Authors: Koen Debackere, Lukas Marcelis, Sofie Demeyer, Marlies Vanden Bempt, Gregor Verhoef, Lucienne Michaux, Thomas Tousseyn, Jan Cools, Daan Dierickx
- Tyrosine Kinase Inhibitor Discontinuation in Patients with Chronic Myelogenous Leukaemia: A Retrospective Study and Review of the Literature(2021)
Authors: Nancy Boeckx, Timothy Devos, Peter Vandenberghe, Gregor Verhoef
Pages: 52 - 58 - Quantitative Whole-Body Diffusion-weighted MRI after One Treatment Cycle for Aggressive Non-Hodgkin Lymphoma Is an Independent Prognostic Factor of Outcome(2021)
Authors: Oliver Bechter, Daan Dierickx, Ann Janssens, Gregor Verhoef, Raymond Oyen, Michel Koole, Vincent Vandecaveye
- Phase 2 study of parsaclisib (INCB050465), a highly selective, next-generation PI3Kδ inhibitor, in relapsed or refractory diffuse large B-cell lymphoma (CITADEL-202)(2021)
Authors: Gregor Verhoef
Pages: 368 - 376 - Rituximab-CHOP With Early Rituximab Intensification for Diffuse Large B-Cell Lymphoma: A Randomized Phase III Trial of the HOVON and the Nordic Lymphoma Group (HOVON-84)(2020)
Authors: Gregor Verhoef